Nektar Therapeutics financials
$59.24−1.92%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $55.2M | $98.4M | $90.1M | $92.1M | $101.9M | $152.9M | $114.6M | $1.19B | $307.7M | $165.4M |
| Gross profit | $55.2M | $67.7M | $56.4M | $70.4M | $77.0M | $133.4M | $93.2M | $1.17B | $277.2M | $135.2M |
| Gross margin | 100.0% | 68.8% | 62.5% | 76.5% | 75.6% | 87.3% | 81.4% | 98.0% | 90.1% | 81.7% |
| Operating income | -$140.1M | -$145.6M | -$263.7M | -$376.2M | -$446.1M | -$425.1M | -$440.0M | $687.9M | -$59.6M | -$112.9M |
| Net income | -$164.1M | -$119.0M | -$276.1M | -$368.2M | -$523.8M | -$444.4M | -$440.7M | $681.3M | -$96.7M | -$153.5M |
| Net margin | −297.1% | −120.9% | −306.3% | −400.0% | −514.0% | −290.6% | −384.5% | 57.1% | −31.4% | −92.8% |
| Diluted EPS | $-9.73 | $-8.68 | $-21.75 | $-29.55 | $-42.90 | $-37.35 | $-37.80 | $56.70 | $-9.30 | $-16.50 |
| EBITDA | -$129.7M | -$125.5M | -$127.4M | -$227.2M | -$432.0M | -$365.7M | -$426.9M | $698.8M | -$28.9M | -$97.5M |
| Operating cash flow | -$208.5M | -$175.7M | -$192.6M | -$304.0M | -$412.7M | -$313.3M | -$328.7M | $718.2M | -$80.4M | -$117.0M |
| Free cash flow | -$208.7M | -$177.2M | -$193.5M | -$309.7M | -$427.6M | -$320.5M | -$355.0M | $704.0M | -$90.1M | -$123.4M |
| Diluted shares | 16.9M | 13.7M | 12.7M | 12.5M | 12.2M | 11.9M | 11.7M | 12.0M | 10.4M | 9.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $15.1M | $44.3M | $35.3M | $88.2M | $25.2M | $199.0M |
| Short-term investments | $230.6M | $211.0M | $268.3M | $416.8M | $708.7M | $862.9M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $195.4M | $200.3M |
| Total assets | $280.4M | $303.9M | $398.0M | $710.6M | $1.12B | $1.54B |
| Total liabilities | $190.6M | $243.1M | $267.0M | $344.0M | $437.7M | $461.5M |
| Shareholders' equity | $89.8M | $60.7M | $131.0M | $366.6M | $679.5M | $1.08B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology